John O. Hackman
Profile
John O.
Hackman has been Vice President of Biometrics and Statistics for Allos Therapeutics, Inc. since March 2003.
Previously, he was Senior Director of Biometrics and Statistics for Allos Therapeutics from February 2001 to February 2003 and Director of Biometrics and Statistics from December 1997 to March 2001.
Prior to joining Allos Therapeutics, Mr. Hackman was Associate Director of Biometrics for Pfizer Central Research from 1996 to 1997.
He has held various positions during his 20 years of experience in the pharmaceutical industry, including positions with Pfizer, Inc., Miles, Inc., Rhone-Poulenc and CytRx Corporation.
Mr. Hackman received an MS degree from North Carolina State University.
Former positions of John O. Hackman
| Companies | Position | End |
|---|---|---|
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Corporate Officer/Principal | - |
Training of John O. Hackman
| North Carolina State University | Graduate Degree |
Experiences
Positions held
Linked companies
| Private companies | 1 |
|---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
- Stock Market
- Insiders
- John O. Hackman
